| 0.378 -0.006 (-1.56%) | 05-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.48 | 1-year : | 0.52 |
| Resists | First : | 0.41 | Second : | 0.44 |
| Pivot price | 0.38  |
|||
| Supports | First : | 0.36 | Second : | 0.29 |
| MAs | MA(5) : | 0.37 | MA(20) : | 0.39 |
| MA(100) : | 0.61 |
MA(250) : | 1.02 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.7 | D(3) : | 25.3 |
| RSI | RSI(14): 30.8 | |||
| 52-week | High : | 4.44 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NBSE ] has closed above bottom band by 35.9%. Bollinger Bands are 82.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.38 - 0.38 | 0.38 - 0.38 |
| Low: | 0.37 - 0.38 | 0.38 - 0.38 |
| Close: | 0.37 - 0.38 | 0.38 - 0.38 |
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Mon, 06 May 2024
NeuBase Therapeutics to delist from Nasdaq next week - The Business Journals
Fri, 05 Apr 2024
NeuBase faces Nasdaq delisting over late annual report - Investing.com
Tue, 26 Mar 2024
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today? - InvestorPlace
Sat, 24 Feb 2024
NeuBase Therapeutics Plans Dissolution and Asset Liquidation - TipRanks
Fri, 23 Feb 2024
NeuBase Therapeutics board approves plan to dissolve company - The Business Journals
Wed, 06 Sep 2023
NeuBase Therapeutics (NASDAQ: NBSE) Stake Acquisition: Symetryx Urges Board to Consider $1 per Share Dividend - Micro Cap Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 11.8 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 149 (K) |
| EPS | -18.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -93.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|